Ehsan Khalilipur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ehsan Khalilipur has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Ata Firouzi
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Institute, Tehran, Iran (the Islamic Republic of)
10 shared publicationsArmin Elahifar
Cardiovascular Intervention Research Center Rajaie Cardiovascular Institute Tehran Iran
8 shared publicationsMohammadreza Baay
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Institute, Tehran, Iran (the Islamic Republic of)
7 shared publicationsSeifollah Abdi
Cardiovascular Intervention Research Center Rajaie Cardiovascular Institute Tehran Iran
5 shared publications- Ata Firouzi
Cardiovascular Intervention Research Center Rajaie Cardiovascular Institute Tehran Iran
4 shared publications - Parham Sadeghipour
Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Medical and Research Institute, Tehran, Iran
4 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- 23 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 572-583
Open AccessCoated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial
Aims: Although enteric-coated aspirin is widely used instead of chewable formulations in patients with atherosclerotic cardiovascular disease (ASCVD), its effects on cardiovascular and gastrointestinal outcomes remain uncertain. Separately, air pollution is a driver of cardiovascular risk, yet individual-level interventions have not been tested in outcomes trials. Methods and results: The Coated Or Chewable Aspirin in Patients with Established AThErosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of AIR Pollution (COATED-AIR) is a randomized trial with a 2 × 2 factorial design planned to address these knowledge gaps. Patients with ASCVD receiving low-dose aspirin are considered for inclusion. Major exclusion criteria consist of being within 72 h of acute/unstable ASCVD or revascularization, triple antithrombotic therapy, active/recent bleeding, life expectancy <1 year, or other barriers or unwillingness for enrolment. Eligible consenting patients are randomized, in a double-blind fashion, to enteric-coated vs. chewable aspirin 81 mg daily and (via factorial randomization) to a hybrid strategy to mitigate the adverse effects of air pollution vs. usual care. The hybrid strategy includes (i) an educational flashcard, (ii) real-time air quality alerts via cellular text messages, and (iii) recommendations to (a) limit outdoor activity or (b) use a KN-95 facemask when outdoors, or (c) increase citrus fruit intake on days with elevated pollution levels. The primary efficacy outcome for the aspirin randomization is a composite of fatal/non-fatal ischaemic stroke, thrombotic/thromboembolic myocardial infarction, and acute limb ischaemia. For the AIR randomization, other forms of cardiovascular death are additionally included in the primary composite outcome. The median planned duration of follow-up is 2 years. Enrolment was completed on 28 January 2026. Clinical follow-up and blinded event adjudications are ongoing. Conclusion: COATED-AIR will determine whether aspirin coating affects its safety or effectiveness, and whether individual-level strategies can mitigate cardiovascular risks from air pollution in patients with ASCVD.
- Open Access
- 19 September 2026
- Published by Elsevier in Cardiovascular Revascularization Medicine: Interesting Cases
- Vol. 14
Medical management for coronary embolism post-AVR: An alternative to invasive therapies
- 19 September 2026
- Published by Elsevier in Cardiovascular Revascularization Medicine: Interesting Cases
- Vol. 14
Open AccessMedical management for coronary embolism post-AVR: An alternative to invasive therapies
- 8 June 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 578-590
Transcatheter Closure of Paravalvular Leaks: Efficacy, Techniques, and Outcomes From a Single‐Center Prospective Study
Background: Paravalvular leak (PVL) is a complication after prosthetic valve implantation, leading to issues like hemolysis and heart failure. While redo surgery is the standard treatment, it poses significant risks for high‐risk patients. Transcatheter PVL closure has become a less invasive option, with improved efficacy from advanced imaging and device technologies. Aims: This study aims to evaluate the safety, efficacy, and technical strategies of transcatheter PVL closure, including novel approaches like the reverse loop and arteriovenous (AV) rail techniques in a prospective single‐center cohort. Methods: Twenty‐eight high‐risk patients (mean age 57.2 ± 10.1 years) with significant aortic or mitral PVLs underwent transcatheter closure. Procedures were guided by multimodal imaging, assessing technical, procedural, and clinical success rates, along with 6‐month outcomes in NYHA functional class and echocardiographic parameters. Results: Out of 28 procedures, 27 were technically successful (96.4%), with clinical success achieved in 92.9% of patients. Most procedures used transfemoral access, treating aortic PVLs retrogradely and mitral PVLs through various routes. Advanced techniques like reverse loop ( n = 4) and AV rail ( n = 3) were utilized in complex cases. NYHA functional class improved significantly ( p < 0.001), with no significant change in left ventricular ejection fraction. One patient required redo surgery, and one died from sepsis. Conclusion: Transcatheter PVL closure is a safe and effective alternative to redo surgery for selected high‐risk patients. Advanced imaging and access techniques enhance procedural success, particularly in complex mitral PVLs. Further multicenter studies with long‐term follow‐up are needed to confirm these results and refine technique selection.
- 8 June 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 578-590
Transcatheter Closure of Paravalvular Leaks: Efficacy, Techniques, and Outcomes From a Single‐Center Prospective Study
Background: Paravalvular leak (PVL) is a complication after prosthetic valve implantation, leading to issues like hemolysis and heart failure. While redo surgery is the standard treatment, it poses significant risks for high‐risk patients. Transcatheter PVL closure has become a less invasive option, with improved efficacy from advanced imaging and device technologies. Aims: This study aims to evaluate the safety, efficacy, and technical strategies of transcatheter PVL closure, including novel approaches like the reverse loop and arteriovenous (AV) rail techniques in a prospective single‐center cohort. Methods: Twenty‐eight high‐risk patients (mean age 57.2 ± 10.1 years) with significant aortic or mitral PVLs underwent transcatheter closure. Procedures were guided by multimodal imaging, assessing technical, procedural, and clinical success rates, along with 6‐month outcomes in NYHA functional class and echocardiographic parameters. Results: Out of 28 procedures, 27 were technically successful (96.4%), with clinical success achieved in 92.9% of patients. Most procedures used transfemoral access, treating aortic PVLs retrogradely and mitral PVLs through various routes. Advanced techniques like reverse loop ( n = 4) and AV rail ( n = 3) were utilized in complex cases. NYHA functional class improved significantly ( p < 0.001), with no significant change in left ventricular ejection fraction. One patient required redo surgery, and one died from sepsis. Conclusion: Transcatheter PVL closure is a safe and effective alternative to redo surgery for selected high‐risk patients. Advanced imaging and access techniques enhance procedural success, particularly in complex mitral PVLs. Further multicenter studies with long‐term follow‐up are needed to confirm these results and refine technique selection.
- Open Access
Impact of advanced cardiac damage in severe aortic stenosis on short-term and mid-term mortality and rehospitalisation after transcatheter aortic valve implantation: a systematic review and meta-analysis
Background Severe aortic stenosis (AS) is commonly associated with advanced cardiac damage, including right ventricular dysfunction (RVD), pulmonary hypertension (PH) and tricuspid regurgitation (TR), which may worsen prognosis after transcatheter aortic valve implantation (TAVI). This systematic review and meta-analysis aimed to assess the effect of these conditions on short-term and mid-term mortality and rehospitalisation following TAVI. Methods We conducted a systematic search of PubMed, Scopus and Web of Science for studies published up to June 2025. Eligible studies included adults with AS undergoing TAVI and reported outcomes at 1 month, 6 months or 12 months stratified by the presence of RVD, PH or TR. Studies had to report either HRs, risk ratios (RRs) or sufficient raw event data for mortality or rehospitalisation. Data were synthesised using a random-effects meta-analysis. Subgroup analyses were conducted by cardiac damage severity according to the Généreux staging system and stratified by valve type and diagnostic modality. Risk of bias in included studies was assessed using the Joanna Briggs Institute’s checklist for cohort studies. Meta-regression was performed to explore sources of between-study heterogeneity. Results A total of 34 studies including 26 076 patients met inclusion criteria. Twelve-month HRs for all-cause mortality increased with advancing cardiac damage: borderline stage HR 1.61 (1.22–2.12), stage 3 HR 2.06 (1.63–2.60) and stage 4 HR 2.77 (2.11–3.64). RRs followed a similar trend. Cardiovascular mortality was highest in stage 4 (HR 3.13 (1.20–8.17); RR 2.63 (1.54–4.47)). Rehospitalisation data were limited but suggested elevated risk in stage 3 (RR 1.33 (1.12–1.58)). Meta-regression indicated that age, sex and comorbidities contributed to between-study heterogeneity, particularly in stage 3 analyses. Conclusion Extravalvular cardiac damage, especially RVD (stage 4), is strongly associated with increased short-term and mid-term mortality and rehospitalisation after TAVI. Even borderline-stage patients face elevated risk, underscoring the continuous nature of AS-related cardiac injury. Incorporating cardiac damage staging into preprocedural assessment can enhance risk stratification and guide management to improve patient outcomes. PROSPERO registration number CRD420250638838.
Open AccessImpact of advanced cardiac damage in severe aortic stenosis on short-term and mid-term mortality and rehospitalisation after transcatheter aortic valve implantation: a systematic review and meta-analysis
Background Severe aortic stenosis (AS) is commonly associated with advanced cardiac damage, including right ventricular dysfunction (RVD), pulmonary hypertension (PH) and tricuspid regurgitation (TR), which may worsen prognosis after transcatheter aortic valve implantation (TAVI). This systematic review and meta-analysis aimed to assess the effect of these conditions on short-term and mid-term mortality and rehospitalisation following TAVI. Methods We conducted a systematic search of PubMed, Scopus and Web of Science for studies published up to June 2025. Eligible studies included adults with AS undergoing TAVI and reported outcomes at 1 month, 6 months or 12 months stratified by the presence of RVD, PH or TR. Studies had to report either HRs, risk ratios (RRs) or sufficient raw event data for mortality or rehospitalisation. Data were synthesised using a random-effects meta-analysis. Subgroup analyses were conducted by cardiac damage severity according to the Généreux staging system and stratified by valve type and diagnostic modality. Risk of bias in included studies was assessed using the Joanna Briggs Institute’s checklist for cohort studies. Meta-regression was performed to explore sources of between-study heterogeneity. Results A total of 34 studies including 26 076 patients met inclusion criteria. Twelve-month HRs for all-cause mortality increased with advancing cardiac damage: borderline stage HR 1.61 (1.22–2.12), stage 3 HR 2.06 (1.63–2.60) and stage 4 HR 2.77 (2.11–3.64). RRs followed a similar trend. Cardiovascular mortality was highest in stage 4 (HR 3.13 (1.20–8.17); RR 2.63 (1.54–4.47)). Rehospitalisation data were limited but suggested elevated risk in stage 3 (RR 1.33 (1.12–1.58)). Meta-regression indicated that age, sex and comorbidities contributed to between-study heterogeneity, particularly in stage 3 analyses. Conclusion Extravalvular cardiac damage, especially RVD (stage 4), is strongly associated with increased short-term and mid-term mortality and rehospitalisation after TAVI. Even borderline-stage patients face elevated risk, underscoring the continuous nature of AS-related cardiac injury. Incorporating cardiac damage staging into preprocedural assessment can enhance risk stratification and guide management to improve patient outcomes. PROSPERO registration number CRD420250638838.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Cardiology
- Vol. 2026 (1) , 9568368
Incidental Coronary Sinus Stenosis During Coronary Angiography: A Rare Angiographic Finding
Background: The coronary sinus (CS) is a major venous drainage pathway of the heart but is rarely the site of clinically significant pathology. When obstruction of the CS occurs, it can lead to serious hemodynamic consequences and a high risk of mortality if not promptly identified. Case Presentation: We report the case of a 60‐year‐old male with Type 2 diabetes mellitus on chronic hemodialysis, who presented with chest pain and dyspnea. While undergoing diagnostic coronary angiography for suspected ischemia, severe stenosis of the CS was incidentally observed. The patient had elevated left ventricular end‐diastolic pressure (LVEDP) and diffuse coronary artery disease. Management included optimization of volume status through intensified hemodialysis, along with guideline‐directed heart failure therapy. The patient′s symptoms and hemodynamic parameters subsequently improved. Conclusion: This case highlights the importance of recognizing rare CS abnormalities during coronary angiography. Although the clinical significance of incidental CS stenosis remains uncertain, awareness of such findings may help guide further evaluation in selected patients.
- 1 January 2026
- Published by Wiley in Case Reports in Cardiology
- Vol. 2026 (1) , 9568368
Open AccessIncidental Coronary Sinus Stenosis During Coronary Angiography: A Rare Angiographic Finding
Background: The coronary sinus (CS) is a major venous drainage pathway of the heart but is rarely the site of clinically significant pathology. When obstruction of the CS occurs, it can lead to serious hemodynamic consequences and a high risk of mortality if not promptly identified. Case Presentation: We report the case of a 60‐year‐old male with Type 2 diabetes mellitus on chronic hemodialysis, who presented with chest pain and dyspnea. While undergoing diagnostic coronary angiography for suspected ischemia, severe stenosis of the CS was incidentally observed. The patient had elevated left ventricular end‐diastolic pressure (LVEDP) and diffuse coronary artery disease. Management included optimization of volume status through intensified hemodialysis, along with guideline‐directed heart failure therapy. The patient′s symptoms and hemodynamic parameters subsequently improved. Conclusion: This case highlights the importance of recognizing rare CS abnormalities during coronary angiography. Although the clinical significance of incidental CS stenosis remains uncertain, awareness of such findings may help guide further evaluation in selected patients.
- 9 November 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 187-193
Short‐Term Cardiac Functional Change Following Transcatheter Atrial Septal Defect Closure: A Prospective Echocardiographic Study
Background: Atrial septal defect (ASD) is a common congenital heart anomaly causing a significant hemodynamic burden if untreated. Transcatheter closure is a minimally invasive standard treatment, but prospective data on short‐term cardiac remodeling are limited. Aims: To evaluate short‐term echocardiographic changes in cardiac structure and function following transcatheter ASD closure in adults. Methods: This prospective observational cohort study included 112 patients aged 15–68 years who underwent transcatheter ASD closure. Comprehensive echocardiography was performed pre‐procedure and at 1 and 6 months postprocedure. Parameters assessed included right and left ventricular dimensions, atrial volumes, right ventricular systolic pressure (RVSP), pulmonary artery pressure (PAP), tricuspid regurgitation (TR) severity, and right ventricular ejection fraction (RVEF). Results: Significant reductions in right atrial volume index (RAVI) by 4.5 ± 5.19 mL/m², right ventricular internal diameter, RVSP by 6.8 ± 9.44 mmHg, PAP decreased by 6.46 ± 8.50 mmHg, and TR severity were observed at 6 months (all p < 0.05). Left ventricular dimensions and ejection fraction remained stable, indicating preserved left‐heart function. RVEF improved in 31% of patients by 6 months. Cardiac rhythm remained unchanged. Notably, reverse remodeling magnitude and timing were independent of baseline ASD size. Conclusion: Transcatheter ASD closure results in early and sustained right‐heart reverse remodeling and pulmonary pressure reduction, without adverse effects on left ventricular function or cardiac rhythm. These consistent benefits, regardless of defect size, support the safety and efficacy of this minimally invasive intervention.
- 9 November 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (1) , 187-193
Short‐Term Cardiac Functional Change Following Transcatheter Atrial Septal Defect Closure: A Prospective Echocardiographic Study
Background: Atrial septal defect (ASD) is a common congenital heart anomaly causing a significant hemodynamic burden if untreated. Transcatheter closure is a minimally invasive standard treatment, but prospective data on short‐term cardiac remodeling are limited. Aims: To evaluate short‐term echocardiographic changes in cardiac structure and function following transcatheter ASD closure in adults. Methods: This prospective observational cohort study included 112 patients aged 15–68 years who underwent transcatheter ASD closure. Comprehensive echocardiography was performed pre‐procedure and at 1 and 6 months postprocedure. Parameters assessed included right and left ventricular dimensions, atrial volumes, right ventricular systolic pressure (RVSP), pulmonary artery pressure (PAP), tricuspid regurgitation (TR) severity, and right ventricular ejection fraction (RVEF). Results: Significant reductions in right atrial volume index (RAVI) by 4.5 ± 5.19 mL/m², right ventricular internal diameter, RVSP by 6.8 ± 9.44 mmHg, PAP decreased by 6.46 ± 8.50 mmHg, and TR severity were observed at 6 months (all p < 0.05). Left ventricular dimensions and ejection fraction remained stable, indicating preserved left‐heart function. RVEF improved in 31% of patients by 6 months. Cardiac rhythm remained unchanged. Notably, reverse remodeling magnitude and timing were independent of baseline ASD size. Conclusion: Transcatheter ASD closure results in early and sustained right‐heart reverse remodeling and pulmonary pressure reduction, without adverse effects on left ventricular function or cardiac rhythm. These consistent benefits, regardless of defect size, support the safety and efficacy of this minimally invasive intervention.
- Open Access
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Single center experience with covered stent closure of sinus venosus atrial septal defect
To evaluate the feasibility, safety, and short-term outcomes of transcatheter closure of sinus venosus atrial septal defect (SVASD) using covered stents. We conducted an institutional retrospective analysis of 24 consecutive patients aged 15–70 years with superior SVASD and significant left-to-right shunting (QP/QS ≥ 1.5), who underwent percutaneous closure using covered stents between June 2021 and December 2023. Pre-procedural imaging included transesophageal echocardiography and cardiac Computed Tomography angiography (CTA). Procedural details, technical success, and echocardiographic parameters were recorded. Post-procedural outcomes were assessed with transthoracic echocardiography and/or CTA. The Patients’ median age was 38 years (IQR: 28–53), and 50% were female. Median Atrial Septal Defect (ASD) size was 15 mm (IQR: 11–19), and median QP/QS ratio decreased from 1.8 (IQR: 1.7–1.95) to 1.1 (IQR: 1.0–1.25) after closure (p < 0.001). Covered stents were used in all cases, and 13 patients (54.1%) required additional non-covered stent support. Technical success was achieved in 96% of patients, with one case of device embolization requiring surgical intervention. Minor complications occurred in 7 patients (29.1%), including hematoma and asymptomatic thrombosis. No mortality was observed. At 3 months, right ventricular dysfunction and enlargement significantly improved (p = 0.004 and p = 0.001, respectively), while right atrial size remained unchanged (p = 0.317). Catheter-based repair of SVASD is feasible, safe, and effective with a low rate of complications. This approach may offer a minimally invasive alternative to surgery in anatomically suitable patients.
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessSingle center experience with covered stent closure of sinus venosus atrial septal defect
To evaluate the feasibility, safety, and short-term outcomes of transcatheter closure of sinus venosus atrial septal defect (SVASD) using covered stents. We conducted an institutional retrospective analysis of 24 consecutive patients aged 15–70 years with superior SVASD and significant left-to-right shunting (QP/QS ≥ 1.5), who underwent percutaneous closure using covered stents between June 2021 and December 2023. Pre-procedural imaging included transesophageal echocardiography and cardiac Computed Tomography angiography (CTA). Procedural details, technical success, and echocardiographic parameters were recorded. Post-procedural outcomes were assessed with transthoracic echocardiography and/or CTA. The Patients’ median age was 38 years (IQR: 28–53), and 50% were female. Median Atrial Septal Defect (ASD) size was 15 mm (IQR: 11–19), and median QP/QS ratio decreased from 1.8 (IQR: 1.7–1.95) to 1.1 (IQR: 1.0–1.25) after closure (p < 0.001). Covered stents were used in all cases, and 13 patients (54.1%) required additional non-covered stent support. Technical success was achieved in 96% of patients, with one case of device embolization requiring surgical intervention. Minor complications occurred in 7 patients (29.1%), including hematoma and asymptomatic thrombosis. No mortality was observed. At 3 months, right ventricular dysfunction and enlargement significantly improved (p = 0.004 and p = 0.001, respectively), while right atrial size remained unchanged (p = 0.317). Catheter-based repair of SVASD is feasible, safe, and effective with a low rate of complications. This approach may offer a minimally invasive alternative to surgery in anatomically suitable patients.
- Open Access
- 28 May 2025
- Published by Brieflands in International Cardiovascular Research Journal
- Vol. 19 (1)
Acute Neurological Deficits Post Coronary Angiography: A Case Report of Contrast Induced Neurotoxicity and Its Clinical Implications
Introduction: This case report aims to highlight contrast-induced neurotoxicity as a rare but increasingly recognized complication of coronary angiography. Neurological side effects from iodinated contrast agents are rare but increasingly reported, particularly in cardiovascular imaging. Case Presentation: We report a case involving a 51-year-old woman who experienced acute neurological deficits, including incontinence and flaccid quadriplegia, within 30 minutes of undergoing elective coronary angiography, despite being fully oriented. Brain MRI and angiography revealed no acute lesions or obstructions, suggesting contrast-induced neurotoxicity (CIN). The patient received conservative management with intravenous hydration and hydrocortisone, leading to a full recovery within 48 hours. She was discharged in good condition and remained symptom-free at follow-up visits for one month, six months, and a year post-discharge. Conclusions: This case underscores the importance of recognizing CIN as a potential complication of contrast use in imaging procedures. Our literature review highlights the current understanding of CIN mechanisms, typically involving disruption of the blood-brain barrier, and emphasizes that supportive care remains the cornerstone of treatment. Although rare, this occurrence draws attention to the neurological complications that can arise from contrast media, underscoring the need for vigilance and supportive care in post-procedure monitoring. Further clinical studies are crucial to elucidate the pathophysiology of CIN and improve management strategies. Although case reports have limitations in generalizability, this detailed description contributes valuable insights into the presentation and management of CIN, informing future research and clinical practice.
- 28 May 2025
- Published by Brieflands in International Cardiovascular Research Journal
- Vol. 19 (1)
Open AccessAcute Neurological Deficits Post Coronary Angiography: A Case Report of Contrast Induced Neurotoxicity and Its Clinical Implications
Introduction: This case report aims to highlight contrast-induced neurotoxicity as a rare but increasingly recognized complication of coronary angiography. Neurological side effects from iodinated contrast agents are rare but increasingly reported, particularly in cardiovascular imaging. Case Presentation: We report a case involving a 51-year-old woman who experienced acute neurological deficits, including incontinence and flaccid quadriplegia, within 30 minutes of undergoing elective coronary angiography, despite being fully oriented. Brain MRI and angiography revealed no acute lesions or obstructions, suggesting contrast-induced neurotoxicity (CIN). The patient received conservative management with intravenous hydration and hydrocortisone, leading to a full recovery within 48 hours. She was discharged in good condition and remained symptom-free at follow-up visits for one month, six months, and a year post-discharge. Conclusions: This case underscores the importance of recognizing CIN as a potential complication of contrast use in imaging procedures. Our literature review highlights the current understanding of CIN mechanisms, typically involving disruption of the blood-brain barrier, and emphasizes that supportive care remains the cornerstone of treatment. Although rare, this occurrence draws attention to the neurological complications that can arise from contrast media, underscoring the need for vigilance and supportive care in post-procedure monitoring. Further clinical studies are crucial to elucidate the pathophysiology of CIN and improve management strategies. Although case reports have limitations in generalizability, this detailed description contributes valuable insights into the presentation and management of CIN, informing future research and clinical practice.
- Open Access
- 26 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70808
Single‐Center Evaluation of the Myval Balloon‐Expandable Transcatheter Heart Valve: A Follow‐Up Study: A Retrospective Cohort Study
Background and Aims: Our objective is to report our single‐center experience with the novel balloon‐expandable Myval Transcatheter Heart Valve (THV) system in Transcatheter Aortic Valve Replacement (TAVR) procedures. Methods: We conducted a retrospective study on a cohort of consecutive patients who underwent TAVR utilizing Myval THV from September 2021 to August 2023 at a tertiary care cardiac center. We collected baseline characteristics, pre‐ and post‐procedural echocardiographic findings, procedural details, in‐hospital outcomes, VARC‐3 technical success, and complications. Additionally, patients were followed up for 3 months concerning their clinical outcomes. Results: The study population comprised 92 TAVR patients with a mean age of 76.8 ± 7.3 years, 66.3% were male, and the mean STS score was 5.9 ± 3.2%. The most common valve sizes used were 24.5 mm (30.4%), 23 mm (26.1%), and 27.5 mm (17.4%). Pre‐dilation was performed in 32 cases (34.8%), achieving a 93.5% technical success rate. In‐hospital mortality occurred in three patients (3.3%), which included one annulus rupture. Permanent pacemaker implantation was required in six patients (6.5%). Three patients (3.3%) exhibited 3+ paravalvular leakage demonstrated by angiography. The New York Heart Association (NYHA) functional class showed significant improvement from baseline to discharge ( p < 0.0001). At the 3‐month follow‐up, five patients encountered mortality (5.4), and three experienced an episode of stroke or transient ischemic attack (3.2%). Two other patients were hospitalized due to cardiovascular events during the 3‐month follow‐up. Conclusion: The Myval THV shows a favorable safety and efficacy profile in TAVR, with low mortality and complications at 3 months.
- 26 May 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (5) , e70808
Open AccessSingle‐Center Evaluation of the Myval Balloon‐Expandable Transcatheter Heart Valve: A Follow‐Up Study: A Retrospective Cohort Study
Background and Aims: Our objective is to report our single‐center experience with the novel balloon‐expandable Myval Transcatheter Heart Valve (THV) system in Transcatheter Aortic Valve Replacement (TAVR) procedures. Methods: We conducted a retrospective study on a cohort of consecutive patients who underwent TAVR utilizing Myval THV from September 2021 to August 2023 at a tertiary care cardiac center. We collected baseline characteristics, pre‐ and post‐procedural echocardiographic findings, procedural details, in‐hospital outcomes, VARC‐3 technical success, and complications. Additionally, patients were followed up for 3 months concerning their clinical outcomes. Results: The study population comprised 92 TAVR patients with a mean age of 76.8 ± 7.3 years, 66.3% were male, and the mean STS score was 5.9 ± 3.2%. The most common valve sizes used were 24.5 mm (30.4%), 23 mm (26.1%), and 27.5 mm (17.4%). Pre‐dilation was performed in 32 cases (34.8%), achieving a 93.5% technical success rate. In‐hospital mortality occurred in three patients (3.3%), which included one annulus rupture. Permanent pacemaker implantation was required in six patients (6.5%). Three patients (3.3%) exhibited 3+ paravalvular leakage demonstrated by angiography. The New York Heart Association (NYHA) functional class showed significant improvement from baseline to discharge ( p < 0.0001). At the 3‐month follow‐up, five patients encountered mortality (5.4), and three experienced an episode of stroke or transient ischemic attack (3.2%). Two other patients were hospitalized due to cardiovascular events during the 3‐month follow‐up. Conclusion: The Myval THV shows a favorable safety and efficacy profile in TAVR, with low mortality and complications at 3 months.
- Open Access
- 25 February 2025
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 41, 2
Rivaroxaban versus Enoxaparin in Patients with Radial Artery Occlusion after Transradial Coronary Catheterization: A Pilot Randomization Trial
Mohsen Maadani, Soudabeh Shafiee Ardestani, Farnaz Rafiee, Kiara Rezaei-Kalantari, Parham Rabiee, Yasmin Mohtasham Kia, Ali Zahedmehr, Bahram Mohebbi, Armin Elahifar, Ehsan Khalilipur, Ata Firouzi, and Parham Sadeghipour. Vasc Specialist Int 2025;41:. https://doi.org/10.5758/vsi.240103
- 25 February 2025
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 41, 2
Open AccessRivaroxaban versus Enoxaparin in Patients with Radial Artery Occlusion after Transradial Coronary Catheterization: A Pilot Randomization Trial
Mohsen Maadani, Soudabeh Shafiee Ardestani, Farnaz Rafiee, Kiara Rezaei-Kalantari, Parham Rabiee, Yasmin Mohtasham Kia, Ali Zahedmehr, Bahram Mohebbi, Armin Elahifar, Ehsan Khalilipur, Ata Firouzi, and Parham Sadeghipour. Vasc Specialist Int 2025;41:. https://doi.org/10.5758/vsi.240103